Assessment of the safety of nicotinamide mononucleotide (NMN) in healthy subjects; phase I study. The clinical trial to evaluate metabolic-syndrome-related parameters to develop NMN as Foods with Function Claims.
Phase 1
- Conditions
- healthy subjects
- Registration Number
- JPRN-UMIN000021309
- Lead Sponsor
- Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1 the subjects with a previous history of diseases. 2 the subjects with malignant neoplasms. 3 the subjects with serious infections. 4 the subjects with psychiatric disorders. 5 the subjects with ophthalmic disorder. 6 the subjects with allergic disorders. 7 the subjects who are regarded as inadequate by the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the safety of NMN (physical and laboratory examinations).
- Secondary Outcome Measures
Name Time Method the kinetics of NMN.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of NMN influence NAD+ biosynthesis in metabolic syndrome parameters?
How does NMN compare to nicotinamide riboside in improving metabolic syndrome biomarkers?
Which biomarkers correlate with NMN efficacy in lipid metabolism or insulin sensitivity?
What adverse events were observed in JPRN-UMIN000021309's phase I NMN trial and their management?
Are there combination therapies involving NMN and SIRT1 activators for metabolic syndrome?